Erratum: Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia (European Journal of Human Genetics (2006) vol. 14 (1240-1247) 10.1038/sj.ejhg.5201700);Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia

European Journal of Human Genetics

Volumn 14, Issue 12, 2006, Pages 1240-1247

  Heuertz, Solange ^a   Le Merrer, Martine ^a   Zabel, Bernhard ^b   Wright, Michael ^c   Legeai Mallet, Laurence ^a   Cormier Daire, Valérie ^a   Gibbs, Linda ^a   Bonaventure, Jacky ^d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ACHONDROPLASIA; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXON; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SCREENING; HUMAN; HYPOCHONDROPLASIA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RESIDUE ANALYSIS;

EID: 33751330697     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201745     Document Type: Erratum

References (27)

1. Hall BD, SpraCger J: Hypochondroplasia: clinical and radiological aspects in 39 cases. Radiology 1979; 133: 95-100.
2. Matsui Y, Yasui N, Kimura T et al: Genotype phenotype correlation in achondroplasia and hypochondroplasia. J Bone Joint Surg (British) 1998; 80B: 1052-1056.
3. Rousseau F, Bonaventure J, Legeai-Mallet L et al: Mutations in the gene encoding fibroblast growth factor receptor 3 in achondroplasia. Nature 1994; 371: 252-254.
4. Shiang R, Thompson LM, Zhu YZ et al: Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994; 78: 335-342.
5. Bellus G, McIntosh I, Smith EA et al: A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995; 10: 357-359.
6. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
7. Grigelioniené G, Hagenas L, Eklof O et al: A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Hum Mut 1998; 11: 333.
8. Thauvin-Robinet C, Faivre L, Lewin P et al: Hypochondroplasia and stature within normal limits: Another family with an Asn540Ser mutation in the fibroblast growth factor receptor 3 gene. Am J Med Genet 2003; 119A: 81-84.
9. Bellus G, Spector EB, Speiser P et al: Distinct missense mutations of the FGFR3 Lys 650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia. Am J Hum Genet 2000; 67: 1411-1421.
10. Winterpacht A, Hilbert K, Stelzer C et al: A novel mutation in FGFR3 disrupts a putative N-glycosylation site and results in hypochondroplasia. Physiol Genomics 2000; 2: 9-12.
11. Rousseau F, Bonaventure J, Mallet L et al: Clinical and genetic heterogeneity of hypochondroplasia. J Med Genet 1996; 33: 749-752.
12. Stoilov I, Kilpatrick MW, Tsipouras P: A common FGFR3 gene mutation is present in achondroplasia but not in hypochondroplasia. Am J Med Genet 1995; 55: 127-133.
13. Grigelioniené G, Eklof O, Laurencikas E et al: Asn540Lys mutation in fibroblast growth factor receptor 3 and phenotype in hypochondroplasia. Acta Paediatr 2000; 89: 1072-1076.
14. Vajo Z, Francomano CA, Wilkin DJ: The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: The achondroplasia family of skeletal dsyplasias, Muenke craniosynostosis and Crouzon syndrome with Acanthosis Nigricans. Endocr Rev. 2000; 21: 23-39.
15. Wilkie AOM: Bad bones, absent smellT selfish testes: the pleitropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 2005; 16: 187-203.
16. Tavormina PL, Shiang R, Thompson L et al: Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 1995; 9: 321-328.
17. Rousseau F, El Ghouzzi V, Delezoide A-L et al: Missense FGFR-3 mutations create cysteine residues in thanatophoric dwarfism type I (TD 1). Hum Mol Genet 1996; 5: 509-512.
18. Bellus G, Gaudenz K, Zackai EH et al: Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nat Genet 1996; 14: 174-176.
19. Kan S-H, Elanko N, Johnson D et al: Genomic screening of fibroblast growth factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Am J Hum Genet 2002; 70: 472-486.
20. Olsen SK, Ibrahimi OA, Raucci A et al: Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci USA 2004; 101: 935-940.
21. Adar R, Monsonego-Ornan E, David P, Yayon A: Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J Bone Min Res 2002; 17: 860-868.
22. Naski MC, Wang Q, Xu J, Ornitz D: Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 1996; 13: 233-237.
23. Lievens PM-J, Liboi E: The thanatophoric dysplasia type II mutation hampers complete maturation of FGF receptor 3 which activates STAT1 from the endoplasmic reticulum. J Biol Chem 2003; 278: 17344-17349.
24. Lievens PM-J, Mutinelli C, Baynes D, Liboi E: The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J Biol Chem 2004; 279: 43254-43260.
25. Wang F, Kan M, Yan G et al: Alternatively spliced NH2-terminal immunoglobulin-like loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1. J Biol Chem 1995; 270: 10231-10235.
26. Sternberg MJE, Gullick WJ: Neu receptor dimerization. Nature 1989; 339: 587.
27. Sternberg MJE, Gullick WJ: A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Eng 1990; 3: 245-248.